CN104800255A - 紫椴花提取物在制备失眠症治疗药物中的应用 - Google Patents
紫椴花提取物在制备失眠症治疗药物中的应用 Download PDFInfo
- Publication number
- CN104800255A CN104800255A CN201510235232.XA CN201510235232A CN104800255A CN 104800255 A CN104800255 A CN 104800255A CN 201510235232 A CN201510235232 A CN 201510235232A CN 104800255 A CN104800255 A CN 104800255A
- Authority
- CN
- China
- Prior art keywords
- extract
- tilia amurensis
- flower
- extractive
- tilia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000793823 Tilia amurensis Species 0.000 title claims abstract description 108
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 title claims abstract description 37
- 206010022437 insomnia Diseases 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 239000003814 drug Substances 0.000 title claims abstract description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 84
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N methyl alcohol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 41
- MQVRGDZCYDEQML-UHFFFAOYSA-N Astragalin Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 MQVRGDZCYDEQML-UHFFFAOYSA-N 0.000 claims abstract description 21
- JPUKWEQWGBDDQB-QSOFNFLRSA-N kaempferol 3-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O JPUKWEQWGBDDQB-QSOFNFLRSA-N 0.000 claims abstract description 21
- 239000002904 solvent Substances 0.000 claims abstract description 14
- 239000011259 mixed solution Substances 0.000 claims abstract description 11
- 238000004128 high performance liquid chromatography Methods 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- 239000007864 aqueous solution Substances 0.000 claims abstract description 5
- 238000010828 elution Methods 0.000 claims abstract description 5
- 238000004064 recycling Methods 0.000 claims abstract description 4
- 238000010898 silica gel chromatography Methods 0.000 claims abstract description 4
- 239000000284 extract Substances 0.000 claims description 90
- 238000010992 reflux Methods 0.000 claims description 36
- 239000000843 powder Substances 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 230000000694 effects Effects 0.000 claims description 30
- 229930182470 glycoside Natural products 0.000 claims description 28
- 150000002338 glycosides Chemical class 0.000 claims description 28
- 239000007788 liquid Substances 0.000 claims description 22
- 240000007591 Tilia tomentosa Species 0.000 claims description 17
- 235000010840 Tilia tomentosa Nutrition 0.000 claims description 17
- 239000000287 crude extract Substances 0.000 claims description 15
- UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 claims description 14
- 239000002024 ethyl acetate extract Substances 0.000 claims description 14
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 9
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 claims description 9
- 238000005242 forging Methods 0.000 claims description 9
- 229910052709 silver Inorganic materials 0.000 claims description 9
- 239000004332 silver Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 7
- 238000000622 liquid--liquid extraction Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 238000000638 solvent extraction Methods 0.000 claims description 7
- 239000003480 eluent Substances 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 238000013461 design Methods 0.000 claims description 3
- 238000012797 qualification Methods 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 229960001866 silicon dioxide Drugs 0.000 claims description 3
- 239000000469 ethanolic extract Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 9
- 238000002474 experimental method Methods 0.000 abstract description 8
- 241001465754 Metazoa Species 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 4
- 206010012335 Dependence Diseases 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 abstract 3
- DVGGLGXQSFURLP-FIZCXTQCSA-N potengriffioside A Natural products O[C@@H]1[C@@H](COC(=O)C=Cc2ccc(O)cc2)O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)cc2)[C@H](O)[C@H]1O DVGGLGXQSFURLP-FIZCXTQCSA-N 0.000 abstract 3
- LTRRTGCXRIMDTF-UHFFFAOYSA-N tiliroside Natural products OC1C(COC(=O)C=Cc2ccc(O)cc2)OC(OC3=C(Oc4cc(O)cc(O)c4C3)c5ccc(O)c(O)c5)C(O)C1O LTRRTGCXRIMDTF-UHFFFAOYSA-N 0.000 abstract 3
- DVGGLGXQSFURLP-VWMSDXGPSA-N tribuloside Chemical compound C([C@@H]1[C@H]([C@@H]([C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1)O)O)OC(=O)\C=C\C1=CC=C(O)C=C1 DVGGLGXQSFURLP-VWMSDXGPSA-N 0.000 abstract 3
- 238000004440 column chromatography Methods 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 abstract 1
- 238000000605 extraction Methods 0.000 description 24
- 239000000243 solution Substances 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 238000003304 gavage Methods 0.000 description 10
- 239000013558 reference substance Substances 0.000 description 9
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 description 8
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 8
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 8
- 238000010171 animal model Methods 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000003208 petroleum Substances 0.000 description 7
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 6
- 229960002275 pentobarbital sodium Drugs 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000004622 sleep time Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 230000000147 hypnotic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 230000028527 righting reflex Effects 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 230000001550 time effect Effects 0.000 description 3
- 206010003084 Areflexia Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 230000001760 anti-analgesic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 241000907897 Tilia Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940125368 controlled substance Drugs 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000874 microwave-assisted extraction Methods 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000004617 sleep duration Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 229960000820 zopiclone Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510235232.XA CN104800255B (zh) | 2015-05-11 | 2015-05-11 | 紫椴花提取物在制备失眠症治疗药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510235232.XA CN104800255B (zh) | 2015-05-11 | 2015-05-11 | 紫椴花提取物在制备失眠症治疗药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104800255A true CN104800255A (zh) | 2015-07-29 |
CN104800255B CN104800255B (zh) | 2018-08-10 |
Family
ID=53685743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510235232.XA Active - Reinstated CN104800255B (zh) | 2015-05-11 | 2015-05-11 | 紫椴花提取物在制备失眠症治疗药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104800255B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110946886A (zh) * | 2019-12-23 | 2020-04-03 | 武汉轻工大学 | 一种椴树花黄酮提取物及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1733788A (zh) * | 2005-06-23 | 2006-02-15 | 浙江工业大学 | 一种从结香花中提取分离银椴苷的方法 |
CN101693037A (zh) * | 2009-10-21 | 2010-04-14 | 中国人民解放军第二军医大学 | 黄酮苷类化合物在制备治疗疟疾的药物中应用 |
CN102304161A (zh) * | 2011-07-06 | 2012-01-04 | 南京泽朗医药科技有限公司 | 一种提取纯化银椴苷的方法 |
CN103627562A (zh) * | 2013-12-15 | 2014-03-12 | 山东轻工业学院 | 一种紫椴花半甜加香葡萄酒及其酿造工艺 |
-
2015
- 2015-05-11 CN CN201510235232.XA patent/CN104800255B/zh active Active - Reinstated
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1733788A (zh) * | 2005-06-23 | 2006-02-15 | 浙江工业大学 | 一种从结香花中提取分离银椴苷的方法 |
CN101693037A (zh) * | 2009-10-21 | 2010-04-14 | 中国人民解放军第二军医大学 | 黄酮苷类化合物在制备治疗疟疾的药物中应用 |
CN102304161A (zh) * | 2011-07-06 | 2012-01-04 | 南京泽朗医药科技有限公司 | 一种提取纯化银椴苷的方法 |
CN103627562A (zh) * | 2013-12-15 | 2014-03-12 | 山东轻工业学院 | 一种紫椴花半甜加香葡萄酒及其酿造工艺 |
Non-Patent Citations (3)
Title |
---|
E. AGUIRRE-HERN´ANDEZ ETC.: "Pharmacological evaluation of the anxiolytic and sedative effects of Tilia americana L. var. mexicana in mice", 《JOURNAL OF ETHNOPHARMACOLOGY》 * |
福建中医研究所: "《福建药物志 第二册》", 30 April 1983, 福建科学技术出版社 * |
马微微等: "紫椴花的化学成分研究", 《中草药》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110946886A (zh) * | 2019-12-23 | 2020-04-03 | 武汉轻工大学 | 一种椴树花黄酮提取物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104800255B (zh) | 2018-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104435095B (zh) | 王枣子总萜有效部位及其提取方法、应用、组合物 | |
CN102846967B (zh) | 一种治疗头痛的纯组分中药制剂及制备工艺 | |
CN101890084B (zh) | 黑种草子总苷提取物及其制备方法和应用 | |
CN103599144B (zh) | 蜘蛛香环氧环烯醚萜酯有效部位的制备方法 | |
CN102357110B (zh) | 墨旱莲在制备预防和治疗高脂血症的药物中的用途 | |
CN103804334B (zh) | 从毛菊苣中提取c15h18o5方法及其用途 | |
CN104800255B (zh) | 紫椴花提取物在制备失眠症治疗药物中的应用 | |
CN102370674A (zh) | 一种桑寄生提取物及其制备方法与应用 | |
CN102895438B (zh) | 石菖蒲提取物制备治疗老年痴呆症药物的用途 | |
CN103301177A (zh) | 长柱十大功劳总生物碱的制备及其质量控制方法 | |
Guo et al. | The pericarp of Zanthoxylum bungeanum Maxim.: An excellent source for the development of alternative drugs for improving glucose and lipid metabolism disorder related diseases | |
CN110179831A (zh) | 硫磺菌提取物的制药用途 | |
CN104398950A (zh) | 一种菖蒲四味抗癌提取物及其制备方法和应用 | |
CN107746421A (zh) | 化合物dictyopterisinf及其在制备抗肿瘤药物中的应用 | |
CN103006634A (zh) | 元宝草呫酮类化合物在制备抗抑郁药物中的用途 | |
Atsumi et al. | Effects of Atractylodis Lanceae Rhizoma on inflammatory mediator production from the RAW264 macrophage cell line | |
CN105193885A (zh) | 一种羌活提取物及其制备方法和应用 | |
CN106008641A (zh) | 睡茄交酯类化合物及提取方法及用途 | |
CN105287474A (zh) | 茴香酸对羟基苯乙酯的应用 | |
CN102241682A (zh) | 一种瓜馥木碱甲的制备方法 | |
CN102895439B (zh) | 治疗痴呆症的石菖蒲提取物及其提取方法 | |
CN115429786B (zh) | 一种杜松烷型倍半萜化合物的提取方法及其应用 | |
CN104523819B (zh) | 一种紫穗槐提取物及其制备方法 | |
CN102070597A (zh) | 一种酰胺类生物碱及其制备方法 | |
CN104721180B (zh) | 蜘蛛香环烯醚萜部位在制备n-型钙通道抑制剂中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180810 Termination date: 20190511 |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
RR01 | Reinstatement of patent right |
Former decision: termination of patent right due to unpaid annual fee Former decision publication date: 20200501 |
|
RR01 | Reinstatement of patent right | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20150729 Assignee: Heilongjiang Yuanmeng Health Industry Development Co.,Ltd. Assignor: HEILONGJIANG University OF CHINESE MEDICINE Contract record no.: X2024980006950 Denomination of invention: The application of extracts from Tilia amurensis flowers in the preparation of drugs for treating insomnia Granted publication date: 20180810 License type: Common License Record date: 20240612 |
|
EE01 | Entry into force of recordation of patent licensing contract |